Neuromuscular Research Grant Competitions from Defeat Duchenne Canada and Myotonic Dystrophy Foundation You Can Apply For Today!
Defeat Duchenne Canada:
Defeat Duchenne Canada is now accepting Letters of Intent (LOI) for its 2025 Research Grant Cycle! As the country’s leading funder of Duchenne muscular dystrophy (DMD) specific research, they are committed to supporting groundbreaking projects that improve care, accelerate treatments, and bring us closer to a cure.
The submission portal opened on March 31, 2025, and researchers worldwide are invited to begin the process by submitting LOI by April 28, 2025. Don’t miss this opportunity to apply for funding for innovative Duchenne research.
Learn more and apply today: https://defeatduchenne.ca/granting-process/
Myotonic Dystrophy Foundation:
The Myotonic Dystrophy Foundation (MDF) supports scientific investigations to enhance the quality of life of people living with myotonic dystrophy and advance research focused on finding treatments and a cure for this disease. As a part of this effort, the MDF offers a number of funding opportunities for DM researchers.
2026 Doctoral and Postdoctoral Research Fellowships
Proposals Due: September 5, 2025
Through this effort, the MDF intends to fund doctoral and postdoctoral research fellowships for projects that focus on basic, translational, and/or clinical research or care in myotonic dystrophy.
Read the fellowship guidelines here!
2026 Early Career Scholar Grant
Proposals Due: September 5, 2025
MDF is accepting applications for Early Career Scholar awards to support the retention of passionate early career researchers in the DM field. These awards are available in both basic/translational science and clinical research streams. Through these awards, MDF seeks to retain early-career scholars who are passionate about DM research.
Read next...
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.
New Best Practice Recommendations for SBMA Care in Canada
Congratulations to Dr. Kerri Schellenberg, the team of Canadian experts, NMD4C Steering Committee members and Investigators, on publishing the first Canadian SBMA care guidelines!
Advancing Neuromuscular Research and Care: Highlights from the 2025 NMD4C Annual Meeting
On September 11, NMD4C hosted its 2025 Annual Meeting in Ottawa, bringing together clinicians, researchers, trainees, and partners for a full day of collaboration, strategic dialogue, and community-building.
NMD4C Hosts Inaugural Clinical Summer School to Empower Canada’s Future Neuromuscular Leaders
On September 10–11, NMD4C hosted its inaugural Clinical Summer School in Ottawa, bringing together 19 neuromuscular clinical fellows from across Canada for two days of hands-on training, mentorship, and networking. Led by national experts and co-chaired by Drs. Gordon Jewitt and Marianne Nury, the program complemented NMD4C’s accredited lecture series and fostered peer connection through dedicated community-building sessions.
2026 Neuromuscular Postdoctoral Research Fellowships Funding Competition is Now Open!
Apply Or Share this opportunity with the trainees in your network — Deadline: October 14, 2025. Hosted by Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC)
Announcing the 2026 Neuromuscular Clinical Fellowship Award Recipients
We are excited to share that the 2026 Neuromuscular Clinical Fellowship Awards have been awarded! These fellowships strengthen clinical training in neuromuscular medicine and help prepare the next generation of specialists who will advance neuromuscular care across Canada.